vialaudit

affiliate disclosure · we earn commission on some vendor links. audits, scores, and rankings are independent — vendors do not pay for placement. read more →

VENDOR MATCHUP · AUDITED

Ascension Peptides vs Pepspan

Two audits, side by side. Composite, subscores, shipping, payment, coupons. Ascension Peptides takes the higher composite this cycle.

Composite score

HIGHER COMPOSITE
79
OF 100
VENDOR AUDIT

Ascension Peptides

US-domestic vendor with third-party (Kovera) COAs that absorbed much of the post-Amino-Asylum migration. It sells its GLP-1s under code names (R-10, T-10, S-5), which carries a regulatory-exposure deduction - the COAs name the real molecule even though the storefront does not. Strong public signals otherwise; scored on public data, with no test order placed.

vs
69
OF 100
VENDOR AUDIT

Pepspan

UK-registered EU-shipping peptide vendor (PEPSPAN LTD), incorporated April 2026 and about six months old. Its catalog has grown to around 18 SKUs; Janoshik COAs are now published for a handful of batches with live verify links, but every measured fill we read runs under label. No GLP-1s. Public-data preview.

Subscore breakdown

7 METRICS
METRIC
ASCENSION PEPTIDES
PEPSPAN
Composite · weighted avg
79/100
vs
69/100
Purity / COA
87/100
vs
65/100
Shipping · stated domestic days
3.0d
vs
3.0d
Pricing
80/100
vs
75/100
Support
84/100
vs
63/100
Last reviewed
2026-10-12
vs
2026-10-12
Payment
card, ach
vs
card, crypto

Catalog overlap

ONLY ASCENSION PEPTIDES
retatrutidetirzepatidesemaglutide
BOTH
bpc-157
ONLY PEPSPAN
tb-500ghk-cuepitalonmots-ccjc-1295ipamorelinsermorelinnad-plus

Active coupons

50% off
Ascension PeptidesEXCLUSIVEVIALAUDIT

50% off at checkout — exclusive vialaudit reader code

USE CODE
No active coupon for Pepspan this cycle.

Other matchups

ALL COMPARISONS →
THE ROUNDUP · MONTHLY

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 SUBSCRIBERS·0 SPONSORED ITEMS·11 ISSUES SINCE LAUNCH